Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-07261271 in Healthy Participants
NCT05536440Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2022
- Primary completion
- Feb 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07261271 in inflammatory bowel disease (IBD) (16 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events: SAD Cohort, Number of Participants With Treatment Emergent Adverse Events: MD Cohort and 8 more. Started Oct 2022; status: completed.
02
Drugs
PF-07261271
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT05536440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05536440.